Atara Biotherapeutics Inc. (ATRA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Atara Biotherapeutics Inc... (ATRA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

12.67

0.36 (2.92%)

At close: Jan 15, 2025, 12:34 PM

undefined% (undefined)

Bid	12.6
Market Cap	72.98M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-25.32
PE Ratio (ttm)	-0.5
Forward PE	n/a
Analyst	Buy

Ask	12.7
Volume	220,503
Avg. Volume (20D)	122,373
Open	13.20
Previous Close	12.31
Day's Range	11.40 - 13.20
52-Week Range	6.50 - 39.50
Beta	undefined

About ATRA

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company i...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 16, 2014

Employees 165

Stock Exchange NASDAQ

Ticker Symbol ATRA

Website https://www.atarabio.com

Analyst Forecast

According to 6 analyst ratings, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 53.91% from the latest price.

Buy 50.00%

Hold 33.33%

Sell 16.67%

Stock Forecasts

Next Earnings Release

Atara Biotherapeutics Inc. is scheduled to release its earnings on Mar 27, 2025, before market opens.
Analysts project revenue of $24.75M, reflecting a 482.08% YoY growth and earnings per share of -2.48, making a -82.29% decrease YoY.

Why Price Moved

2 months ago · Source

+22.19%

Atara Biotherapeutics shares are trading higher af... Unlock content with Pro Subscription

4 months ago · Source

Atara Biotherapeutics shares are trading higher. The company announced a $36 million registered direct offering of 758900 shares at $8.25 per share.

News

1 week ago · zacks.com

Here's Why You Should Consider Buying Atara Biotherapeutics Stock

Here, we discuss some reasons why buying ATRA stock now may turn out to be a prudent move.

1 week ago · zacks.com

Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · businesswire.com

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl...

2 months ago · businesswire.com

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

2 months ago · zacks.com

Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $2.93 per share versus the Zacks Consensus Estimate of a loss of $3.77. This compares to loss of $16.50 per share a year ago.

2 months ago · businesswire.com

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

3 months ago · zacks.com

Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.